We conducted a retrospective study on patients with pathological stage II-III PGC who underwent PG or TG from 2013 to 2023. Propensity score-matching was applied to adjust for tumor size and stage between the PG and TG groups at a 1:1 ratio. We evaluated the procedural safety, oncological, and functional outcomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
five-year overall survival
Timeframe: 5 years